Serum Neuron-specific Enolase Levels in Preterm and Term Newborns and in Infants 1–3 Months of Age

Abbasoğlu, Aysel; Sarıalıoğlu, Faık; Yazıcı, Nalan; Bayraktar, Nilüfer; Haberal, A; Erbay, Ayşe

doi:10.1016/j.pedneo.2014.07.005

Cited by 13 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However and notably, pediatric populations were not nearly as frequently studied as adult TBI patients. The reference levels for healthy pediatric populations (especially the first year) of S100B and NSE have both been shown to be significantly higher than for adults (factor ×2–4) (124, 125). Nevertheless, during traumatic conditions, similar trajectories to adults are seen in pediatric populations, and serum dynamics are likely a marker of injury severity and progression not requiring separate reference levels per age group.…”

Section: Discussionmentioning

confidence: 99%

Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review

et al. 2017

View full text Add to dashboard Cite

BackgroundThe proteins S100B, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and neurofilament light (NF-L) have been serially sampled in serum of patients suffering from traumatic brain injury (TBI) in order to assess injury severity and tissue fate. We review the current literature of serum level dynamics of these proteins following TBI and used the term “effective half-life” (t1/2) in order to describe the “fall” rate in serum.Materials and methodsThrough searches on EMBASE, Medline, and Scopus, we looked for articles where these proteins had been serially sampled in serum in human TBI. We excluded animal studies, studies with only one presented sample and studies without neuroradiological examinations.ResultsFollowing screening (10,389 papers), n = 122 papers were included. The proteins S100B (n = 66) and NSE (n = 27) were the two most frequent biomarkers that were serially sampled. For S100B in severe TBI, a majority of studies indicate a t1/2 of about 24 h, even if very early sampling in these patients reveals rapid decreases (1–2 h) though possibly of non-cerebral origin. In contrast, the t1/2 for NSE is comparably longer, ranging from 48 to 72 h in severe TBI cases. The protein GFAP (n = 18) appears to have t1/2 of about 24–48 h in severe TBI. The protein UCH-L1 (n = 9) presents a t1/2 around 7 h in mild TBI and about 10 h in severe. Frequent sampling of these proteins revealed different trajectories with persisting high serum levels, or secondary peaks, in patients with unfavorable outcome or in patients developing secondary detrimental events. Finally, NF-L (n = 2) only increased in the few studies available, suggesting a serum availability of >10 days. To date, automated assays are available for S100B and NSE making them faster and more practical to use.ConclusionSerial sampling of brain-specific proteins in serum reveals different temporal trajectories that should be acknowledged. Proteins with shorter serum availability, like S100B, may be superior to proteins such as NF-L in detection of secondary harmful events when monitoring patients with TBI.

show abstract

Section: Discussionmentioning

confidence: 99%

Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…All six concentrations differed substantially from the other controls (mean > ×10 higher), interpreted as a consequence of the capillary sampling and hence these six observations were excluded. Abbasoglu et al [17] have reported high NSE levels in healthy preterm and term newborns.…”

Section: Concentrations Of Cga Cgb and Nsementioning

confidence: 97%

Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors

Georgantzi

Sköldenberg

Stridsberg

et al. 2018

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Chromogranin A (CgA) and neuron specific enolase (NSE) are important markers in adult neuroendocrine tumors (NET). Neuroblastoma (NB) has certain neuroendocrine properties. The aim of this study was to correlate blood concentrations of CgA, chromogranin B (CgB), and NSE to prognostic factors and outcome in children with NB. Blood samples from 92 patients with NB, 12 patients with benign ganglioneuroma (GN), 21 patients with non-NB solid tumors, 10 patients with acute leukemias, and 69 healthy children, were analyzed. CgA concentrations were higher in neonates vs. children older than one month in the control group (p < 0.0001), and in neonates with NB vs. the control group (p < 0.01). CgA and NSE concentrations were higher in patients with stages 3 and 4 disease (p < 0.05 and p < 0.05), in patients having tumors with amplification of MYCN (p < 0.05 and p < 0.001), or chromosome 1 p deletion (p < 0.05 and p < 0.05). NSE correlated to the tumor size at diagnosis (p < 0.001) and to tumor related death (p < 0.01) in NB. CgA and NSE concentrations were elevated in patients with NB and especially in those with advanced disease. Both CgA and NSE correlated to genetic markers, while only NSE correlated to primary tumor size and outcome in NB. We found that CgA and NSE are clinically valuable tumor markers in NB and they merit prospective clinical evaluations as such.

show abstract

“…LDH is an enzyme that plays an important role in glycolysis and can be used as an indicator of the systemic tumor burden. NSE is also an enzyme takes part in the glycolysis process; it exists in neurons and nerve-derived cells and is a highly specific and sensitive indicator of NB [18] . An LDH concentration of > 1000 U/L and NSE concentration of > 100 ng/ml are poor prognostic factors [19] .…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and prognosis of 40 patients with periorbital metastasis of neuroblastoma

Qin

Zhao

Jin

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundThis study was performed to summarize the clinical characteristics of patients with periorbital metastasis of neuroblastoma (NB) and analyze the short-term prognosis. MethodsThis study included 40 patients with periorbital metastasis of NB from March 2007 to March 2018. The patients' clinical characteristics and short-term prognosis were retrospectively analyzed. ResultsThe 40 patients comprised 25 boys and 15 girls with a median age at onset of 31 months (range, 8-132 months). The patients' symptoms included a periorbital mass and eye bruising (n = 37, 92.5%), limb pain (n = 14, 35.0%), a head and neck mass (n = 8, 20.0%), fever (n = 8, 20.0%), an abdominal mass (n = 4, 10.0%), weakness (n = 3, 7.5%), abdominal pain (n = 2, 5.0%), anemia (n = 2, 5.0%), and others (n = 3, 7.5%). All 40 patients had stage IV, high-risk NB. Various auxiliary structures of the eye were involved: ocular muscles (n = 11, 27.5%), lacrimal glands (n = 4, 10.0%), optic nerve (n = 2, 5.0%), and eyelid (n = 1 2.5%). Fifteen patients (37.5%) had tumor invasion in a periorbital sinus cavity. All patients had bone marrow and bone metastasis. Of 38 patients with a known MYCN gene status, 17 patients (44.7%) had MYCN amplification. The median follow-up duration was 19 months

show abstract

Serum Neuron-specific Enolase Levels in Preterm and Term Newborns and in Infants 1–3 Months of Age

Abstract: Our findings suggest that adult reference values should not be applied to the preterm and term age groups.

Cited by 13 publications

References 27 publications

Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review

Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review

Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors

Clinical characteristics and prognosis of 40 patients with periorbital metastasis of neuroblastoma

Contact Info

Product

Resources

About